|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM114122393 |
| 003 |
DE-627 |
| 005 |
20231222165254.0 |
| 007 |
tu |
| 008 |
231222s2001 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0381.xml
|
| 035 |
|
|
|a (DE-627)NLM114122393
|
| 035 |
|
|
|a (NLM)11513545
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Bleesing, J J
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a TcR-alpha/beta(+) CD4(-)CD8(-) T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis
|
| 264 |
|
1 |
|c 2001
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.09.2001
|
| 500 |
|
|
|a Date Revised 08.04.2022
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2001 Academic Press.
|
| 520 |
|
|
|a Autoimmune lymphoproliferative syndrome (ALPS), caused by inherited defects in apoptosis secondary to mutations in genes encoding Fas/CD95/APO-1 and Fas ligand (Fasl)/CD95L, is characterized by nonmalignant lymphadenopathy and splenomegaly, increased T cell receptor alpha/beta(+) CD4(-)CD8(-) T cells (alpha/beta(+) double-negative T cells [alpha/beta(+)-DNT cells]), autoimmunity, hypergammaglobulinemia, and cytokine abnormalities. The alpha/beta(+)-DNT cells are immunophenotypically and functionally similar to alpha/beta(+)-DNT cells that accumulate in lpr and gld mice, which bear genetic mutations in Fas and FasL. In these mice, alpha/beta(+)-DNT cells express the B-cell-specific CD45R isoform B220. We show that alpha/beta(+)-DNT cells of ALPS patients, with either Fas or FasL mutations, also express B220. In addition, also similar to LPR/gLD mice, they have an unusual population of B220-positive CD4(+) T cells. B220 expression, together with our finding of characteristic lectin binding profiles, demonstrates that cell surface O-linked glycoproteins have undergone specific modifications, which may have consequences for lymphocyte trafficking, cell-cell interactions, and access to alternative apoptosis pathways
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a CD4 Antigens
|2 NLM
|
| 650 |
|
7 |
|a CD8 Antigens
|2 NLM
|
| 650 |
|
7 |
|a Membrane Glycoproteins
|2 NLM
|
| 650 |
|
7 |
|a Polysaccharides
|2 NLM
|
| 650 |
|
7 |
|a Protein Isoforms
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Antigen, T-Cell, alpha-beta
|2 NLM
|
| 650 |
|
7 |
|a Leukocyte Common Antigens
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.3.48
|2 NLM
|
| 700 |
1 |
|
|a Brown, M R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dale, J K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Straus, S E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lenardo, M J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Puck, J M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Atkinson, T P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fleisher, T A
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 100(2001), 3 vom: 01. Sept., Seite 314-24
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:100
|g year:2001
|g number:3
|g day:01
|g month:09
|g pages:314-24
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 100
|j 2001
|e 3
|b 01
|c 09
|h 314-24
|